EDSA (Edesa Biotech) Shares Outstanding (EOP): 8.89 Mil (As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech Shares Outstanding (EOP)?

Edesa Biotech EDSA -3.23% 26 Shares Outstanding (EOP) is 8.89 Mil as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Edesa Biotech's shares outstanding for the quarter that ended in Mar. 2026 was 8.89 Mil.

Edesa Biotech's quarterly shares outstanding increased from Dec. 2025 (8.33 Mil) to Mar. 2026 (8.89 Mil). It means Edesa Biotech issued new shares from Dec. 2025 to Mar. 2026 .

Edesa Biotech's annual shares outstanding increased from Sep. 2024 (3.25 Mil) to Sep. 2025 (7.14 Mil). It means Edesa Biotech issued new shares from Sep. 2024 to Sep. 2025 .


Edesa Biotech  (NAS:EDSA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Edesa Biotech Shares Outstanding (EOP) Related Terms


Edesa Biotech Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech Shares Outstanding (EOP) Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.90 2.38 3.08 3.25 7.14

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.02 7.02 7.14 8.33 8.89

EDSA vs ACET, HRTX, ENTX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Edesa Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Shares Outstanding (EOP) falls into.


EDSA
26GF Score
Edesa Biotech Inc EDSA
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 8.89 Mil mean?
Edesa Biotech (EDSA) has a Shares Outstanding (EOP) of 8.89 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Edesa Biotech and its competitors.
Is Edesa Biotech's Shares Outstanding (EOP) too high?
Edesa Biotech's current Shares Outstanding (EOP) is 8.89 Mil. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Shares Outstanding (EOP) compare to ACET and HRTX?
Edesa Biotech's Shares Outstanding (EOP) of 8.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current Shares Outstanding (EOP) is 8.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Shares Outstanding (EOP) of 8.89 Mil. The current Shares Outstanding (EOP) is 8.89 Mil. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Shares Outstanding (EOP) is 8.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price